NCT00572169View on ClinicalTrials.gov

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Velcade

Will be given in central venous catheter

DRUG

Thalidomide

Capsule taken by mouth

DRUG

Dexamethasone

A pill taken by mouth

DRUG

Adriamycin

Given into the vein (IV) by a continuous infusion through a central catheter

DRUG

Cisplatin

Given into the vein (IV) by a continuous infusion through a central catheter

DRUG

Cyclophosphamide

Given into the vein (IV) by a continuous infusion through a central catheter

DRUG

Etoposide

Given into the vein (IV) by a continuous infusion through a central catheter

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER